EPHA1 and non-small cell lung carcinoma: The same gene has been suggested to harbor driver mutations in melanoma [22], and the Eph family receptors have been implicated in tumor progression and clinical outcome in several malignancies including tongue squamous cell-, ovarian-, gastric-, breast-, non-small cell lung cancer, melanoma and neuroblastoma [23–29].